DESSAU, Germany & ROCKVILLE, Md.--(BUSINESS WIRE)--IDT Biologika, a globally integrated contract manufacturer of vaccines and biopharmaceuticals, accepted a CMO Leadership Award for overall quality, reliability, capabilities, expertise, compatibility and development during a ceremony held yesterday in New York City. Sponsored by Life Science Leadermagazine, the annual awards recognize the top contract manufacturing organizations (CMOs) serving the pharmaceutical and biopharmaceutical industries.
IDT Biologika Chief Executive Officer Dr. Ralf Pfirmann accepted the 2017 CMO Leadership Award on behalf of the company. “With our competence and wide range of capabilities in industrial development and manufacture, IDT is the most helpful partner for all organizations working on new solutions with the mission of bringing new vaccines or biological drugs to patients,” said Dr. Pfirmann. “Our increasing worldwide recognition is based on our dedication to serving these needs. The success of our customers is highlighted by the multiple categories of the CMO award in which we are decorated this year.”
Winners were evaluated based on real-world experiential data and feedback from decision makers who work with contract manufacturing suppliers. IDT was judged by its customers as a top performer among more than 80 CMOs. The company achieved this high honor in all six categories across 30 performance metrics considered important to the selection of a CMO and based on customers’ direct experience working with IDT on an outsourced project within the last 18 months. Life Science Leader teamed up with Industry Standard Research (ISR) to conduct the Contract Manufacturing Quality Benchmarking survey that captured input from decision makers.
The award adds to IDT’s distinguished reputation in the contract services business and celebrates the company’s ongoing commitment to manufacturing excellence. Today, IDT offers a wide range of services during all phases of vaccine and biopharmaceutical development - from early research and process development through clinical and mass commercial manufacturing.
IDT continues to increase its global footprint and has expanded its infrastructure in Dessau, Germany and Rockville, Maryland. The company is particularly focused on developing new medical solutions for the U.S. market and recently become a prime contractor for the Biomedical Advanced Research and Development Authority (BARDA), an office of the U.S. Department of Health and Human Services. For more information, visit IDT Biologika on the web at www.idt-biologika.com.
About IDT Biologika
IDT Biologika is an innovative, privately-held company with nearly 100 years of experience in researching, developing, manufacturing and marketing products for the global protection of human and animal health. The company produces vaccines and pharmaceuticals according to the highest quality standards, for its own animal health products and under contract.
Company sites in Germany include the BioPharmaPark in Dessau-Rosslau and the Riems district of Greifswald. IDT's Animal Health business is marketed internationally from its offices in Denmark, the Netherlands, France, Spain, Poland and Canada. In the United States, IDT Corporation operates a production site for clinical test samples in Rockville, Maryland. In Canada, IDT Biologika subsidiary Gallant Custom Laboratories manufactures autogenous vaccines. The same vaccines are produced by the recently acquired IDT subsidiary in the United Kingdom, Ridgeway Biologicals.
In 2015, IDT Biologika registered sales of $195 million in animal health and contract manufacturing of vaccines and parenteral products. IDT Biologika currently employs around 1,700 workers worldwide.
IDT Biologika is a member of the Klocke Group, which is specialized in contract production and packaging of medications, vaccines and cosmetic products. As a traditional family-owned company, the Klocke Group employs a workforce of more than 2,200 people at eight production sites and sales offices around the world. For more information, visit www.idt-biologika.com.
